Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (307)	5/10/2007 3:03:04 PM
From: Mike McFarland	Respond to of 360

haha I like to play pairs of 6's in Texas Holdem to make a set. I've made my set several times, so I use scary voice at poker nights for laughs.

To: Steve Lokness who wrote (307)	6/18/2007 6:36:45 PM
From: Mike McFarland	Respond to of 360

The shares traded up a dime briefly on that press release today. But only held on to a lousy three cents. Oh well! You can access the PR on the website genelogic.com Ah, "phase R" Listen to Gene Logic's new CEO, Charles Dimmler, discuss our Phase R™ Program and the role drug repositioning can play in pharmaceutical pipeline strategy. Have you listened to it? Charles L. Dimmler III Managing Principal, Newcastle Harbor, LLC. Charles L. Dimmler III has served as a director since May 1996. Mr. Dimmler is Managing Principal of Newcastle Harbor, LLC, a private asset management firm specializing in enterprise development in the field of life sciences. From April 2001 to December 2003, Mr. Dimmler served as Chief Investment Officer of H. Lundbeck A/S, a pharmaceutical company listed on the Copenhagen stock exchange. Simultaneously, Mr. Dimmler served as Chief Executive Officer and Chairman of the Board of Directors of Lundbeck, Inc., a wholly owned subsidiary of H. Lundbeck A/S. From January 2000 to September 2001, Mr. Dimmler served as a Managing Director of Burrill & Company, a private merchant banking firm specializing in the life sciences industry. From August 1988 until December 1999, Mr. Dimmler was General Partner of Hambro International Equity Partners and an investment officer of Cross Atlantic Partners Funds. genelogic.com Couldn't find Newcastle Harbor online, but googled his name and this came up marketvisual.com